HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.

Abstract
Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resistance to these drugs and thus expand the array of cancers that could benefit from them. We show that human cancer cell lines which respond poorly to ABT-888 (a PARPi), become sensitive to it when co-treated with vorinostat (a histone deacetylase inhibitor (HDACi)). Vorinostat also sensitized PARPis insensitive cancer cell lines to 6-thioguanine (6-TG)-a drug that targets PARPis sensitive cells. The sensitizing effect of vorinostat was associated with increased phosphorylation of eukaryotic initiation factor (eIF) 2α which in and of itself increases the sensitivity of cancer cells to ABT-888. Importantly, these drug combinations did not affect survival of normal fibroblasts and breast cells, and significantly increased the inhibition of xenograft tumor growth relative to each drug alone, without affecting the mice weight or their liver and kidney function. Our results show that combination of vorinostat and ABT-888 could potentially prove useful for treatment of cancer with innate resistance to PARPis due to active HRR machinery, while the combination of vorinostat and 6-TG could potentially overcome innate or acquired resistance to PARPis due to secondary or reversal BRCA mutations, to decreased PARP-1 level or to increased expression of multiple drug resistant proteins. Importantly, drugs which increase phosphorylation of eIF2α may mimic the sensitizing effect of vorinostat on cellular response to PARPis or to 6-TG, without activating all of its downstream effectors.
AuthorsMichal Yalon, Liron Tuval-Kochen, David Castel, Itai Moshe, Inbal Mazal, Osher Cohen, Camila Avivi, Kineret Rosenblatt, Sarit Aviel-Ronen, Ginette Schiby, Joachim Yahalom, Ninette Amariglio, Raphael Pfeffer, Yaacov Lawrence, Amos Toren, Gideon Rechavi, Shoshana Paglin
JournalPloS one (PLoS One) Vol. 11 Issue 5 Pg. e0155711 ( 2016) ISSN: 1932-6203 [Electronic] United States
PMID27196668 (Publication Type: Journal Article)
Chemical References
  • BRCA1 Protein
  • BRCA1 protein, human
  • Benzimidazoles
  • Carrier Proteins
  • Eukaryotic Initiation Factor-2
  • Hydroxamic Acids
  • Poly(ADP-ribose) Polymerase Inhibitors
  • TXNIP protein, human
  • veliparib
  • Vorinostat
  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1
  • RAD51 protein, human
  • Rad51 Recombinase
  • Thioguanine
Topics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • BRCA1 Protein (metabolism)
  • Benzimidazoles (administration & dosage)
  • Carrier Proteins (metabolism)
  • Cell Line, Tumor
  • Cellular Senescence
  • Drug Resistance, Neoplasm
  • Eukaryotic Initiation Factor-2 (metabolism)
  • Female
  • Fibroblasts (metabolism)
  • Humans
  • Hydroxamic Acids (administration & dosage)
  • MCF-7 Cells
  • Mice
  • Mice, Nude
  • Neoplasm Transplantation
  • Phosphorylation
  • Plasmids (metabolism)
  • Poly (ADP-Ribose) Polymerase-1 (antagonists & inhibitors)
  • Poly(ADP-ribose) Polymerase Inhibitors (therapeutic use)
  • Rad51 Recombinase (metabolism)
  • Recombination, Genetic
  • Thioguanine (administration & dosage)
  • Vorinostat
  • Weight Loss

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: